{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:43:29Z","timestamp":1777571009413,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41375-019-0699-y","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T11:03:02Z","timestamp":1576839782000},"page":"333-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Do persons with chronic myeloid leukaemia have normal or near normal survival?"],"prefix":"10.1038","volume":"34","author":[{"given":"Tomas","family":"Radivoyevitch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davis","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"699_CR1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"},{"key":"699_CR2","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398\u2013406.","journal-title":"Leukemia."},{"key":"699_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon, Guilhot F, Deininger M, Fava C, Nagler A, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553\u201361.","journal-title":"J Natl Cancer Inst"},{"key":"699_CR4","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/cncr.31852","volume":"125","author":"KM Kenzik","year":"2019","unstructured":"Kenzik KM, Bhatia R, Williams GR, Bhatia S. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. Cancer. 2019;125:2570\u20138.","journal-title":"Cancer."},{"key":"699_CR5","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381\u20138.","journal-title":"J Clin Oncol"},{"key":"699_CR6","doi-asserted-by":"publisher","unstructured":"Efficace F, Stagno F, Iurlo A, Breccia M, Cottone F, Bonifacio M, et al. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia. 2019; https:\/\/doi.org\/10.1038\/s41375-019-0563-0.","DOI":"10.1038\/s41375-019-0563-0"},{"key":"699_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol."},{"key":"699_CR8","doi-asserted-by":"crossref","unstructured":"Saglio G, Gale RP. Prospects for achieving therapy-free remission in chronic myeloid leukaemia. Br. J Haematol. 2020. In press.","DOI":"10.1111\/bjh.16506"},{"key":"699_CR9","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","volume":"33","author":"M Houshmand","year":"2019","unstructured":"Houshmand M, Simonetti G, Circosta P, Gaidano V, Cinetti A, Martinelli G, et al. Chronic myeloid leukemia stem cells. Leukemia. 2019;33:1543\u201356.","journal-title":"Leukemia."},{"key":"699_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/leu.2015.258","volume":"30","author":"T Radivoyevitch","year":"2016","unstructured":"Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT, et al. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. Leukemia. 2016;30:285\u201394.","journal-title":"Leukemia."},{"key":"699_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.clml.2015.08.088","volume":"15","author":"SL Goldberg","year":"2015","unstructured":"Goldberg SL. Monitoring chronic myeloid leukemia in the real world: gaps and opportunities. Clin Lymphoma Myeloma Leuk. 2015;15:711\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"699_CR12","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00432-016-2158-8","volume":"142","author":"Q Jiang","year":"2016","unstructured":"Jiang Q, Gale RP. Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. J Cancer Res Clin Oncol. 2016;142:1549\u201355.","journal-title":"J Cancer Res Clin Oncol"},{"key":"699_CR13","unstructured":"Jiang Q, Yu L, Dou X. Impact of socio-demographics on disease phase and risk, drug choice, and treatment outcomes in adults with newly-diagnosed chronic myeloid leukemia. Presented at the 21st Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy. Bordeaux, France."},{"key":"699_CR14","unstructured":"https:\/\/stats.oecd.org\/Index.aspx?DataSetCode=SHA. Accessed 19 Sep 2019."},{"key":"699_CR15","unstructured":"https:\/\/www.who.int\/en\/news-room\/detail\/19-05-2016-life-expectancy-increased-by-5-years-since-2000-but-health-inequalities-persist. Accessed 19 Sep 2019."},{"key":"699_CR16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJMp1507485","volume":"373","author":"A Mehrotra","year":"2015","unstructured":"Mehrotra A, Prochazka A. Improving value in health care-against the annual physical. N. Engl J Med. 2015;373:1485\u20137.","journal-title":"N. Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0699-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0699-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0699-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T10:12:53Z","timestamp":1654855973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0699-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0699-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"assertion":[{"value":"13 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RPG is a part-time employee of Celgene Corp.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}